{
    "code": "60001111",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001111",
    "time": "2022-01-14 06:11:00",
    "許可證字號": "衛部菌疫輸字第001111號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "113\/08\/21",
    "發證\/登錄日期": "108\/08\/21",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000111106",
    "中文品名": "康癌停凍晶注射劑420毫克",
    "英文品名": "KANJINTI Powder for concentrate for solution for infusion 420mg",
    "適應症": "一、Kanjinti應使用於下列HER2過度表現或HER2基因amplification之早期乳癌、轉移性乳癌病人，說明：\r\n1.早期乳癌(EBC)：\r\n(1) 經外科手術、化學療法(術前或術後)之輔助療法。(2) 以doxorubicin與 cyclophosphamide治療，再合併paclitaxel或docetaxel之輔助療法。(3) 與docetaxel及carboplatin併用之輔助療法。(4) 術前與化學療法併用和術後之輔助療法使用於治療局部晚期(包括炎症)乳癌或腫瘤(直徑>2厘米)。\r\n2.轉移性乳癌(MBC)：\r\n(1) 單獨使用於曾接受過一次(含)以上化學療法之轉移性乳癌；除非病人不適合使用anthracycline或taxane，否則先前之化學治療應至少包括anthracycline或taxane。使用於荷爾蒙療法失敗之荷爾蒙受體陽性之病人，除非病人不適用荷爾蒙療法。(2) 與paclitaxel或docetaxel併用於未曾接受過化學療法之轉移性乳癌。(3) 與芳香環酶抑制劑併用於荷爾蒙受體陽性之轉移性乳癌。\r\n二、轉移性胃癌(mGC)：Kanjinti合併capecitabine (或5-fluorouracil)及cisplatin適用於未曾接受過化學治療之HER2過度表現轉移性胃腺癌(或胃食道接合處腺癌)的治療。說明：\r\n(1) HER2過度表現之檢測方法須經衛生主管機關核准(用於胃癌之檢驗)，請參照相關檢測套組仿單中適應症，確效(validation)及效能(performance)之敘述。另請參照本仿單[轉移性胃癌]之敘述。\r\n(2) 樞紐試驗確認療效僅顯現於有較高HER2蛋白表現(IHC2+\/FISH+或IHC3+)之族群。HER2次族群分析結果顯示，HER2蛋白表現較低(IHC 0\/FISH+: HR 0.92; IHC1+\/FISH+: HR 1.24)的族群的療效總體提升不高，反之，HER2蛋白表現較高(IHC2+\/FISH+: HR 0.75; IHC 3+\/FISH+: HR 0.58)的族群的療效總體提升較高。",
    "劑型": "243凍晶注射劑",
    "包裝": "420mg玻璃小瓶裝，附溶劑20mL玻璃小瓶裝，100支以下盒裝 420mg玻璃小瓶裝，100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "113\/08\/21",
    "主成分略述": "Trastuzumab",
    "限制項目": "02輸　入 1D須執行風險管理計畫 91生物相似性藥品",
    "申請商名稱": "620117N253  台灣安進藥品有限公司",
    "申請商地址": "臺北市信義區松仁路100號13樓之1、之2",
    "主製造廠": [
        {
            "": "IRELAND",
            "製程": "成品製造廠"
        },
        {
            "": "ITALY",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FNL0121000  PATHEON BIOLOGICS B.V.",
            "製造廠廠址": "ZUIDERWEG 72\/2, 9744 AP GRONINGEN, THE NETHERLANDS",
            "製造廠公司地址": "",
            "製造廠國別": "NETHERLANDS",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "FPR0034000  AMGEN MANUFACTURING,LIMITED",
            "製造廠廠址": "STATE ROAD 31,KM 24.6 JUNCOS,PUERTO RICO 00777-4060",
            "製造廠公司地址": "",
            "製造廠國別": "PUERTO RICO",
            "製程": "二級包裝廠"
        },
        {
            "製造廠名稱": "FUS0866000  IMMUNEX RHODE ISLAND CORPORATION",
            "製造廠廠址": "40 TECHNOLOGY WAY, WEST GREENWICH RHODE ISLAND 02817, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013004800",
            "成分名稱": "Trastuzumab",
            "含量描述": "增量充填約5% (每小瓶充填量為440MG)",
            "含量": "420.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Kanjinti_Photo_02白底尺規藥瓶_2-109-06-10(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "1026792 ART_leaflet_new MAH address-110-10-07(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=005&Type=9"
        },
        {
            "title": "Taiwan_cn_Kanjinti_pi_PI alignment with HER-109-12-01_clean-110-03-29.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=004&Type=9"
        },
        {
            "title": "1026794 ART_420mg ADL carton_new MAH address-110-10-07(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=009&Type=8"
        },
        {
            "title": "1026793 ART_420mg Actavis carton_new MAH address-110-10-07(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=008&Type=8"
        },
        {
            "title": "420mg外盒Amgen-020011110004-110-01-07.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=007&Type=8"
        },
        {
            "title": "420mg(含溶劑)外盒Amgen-020011110003-110-01-07.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=006&Type=8"
        },
        {
            "title": "020011110004-108-09-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=005&Type=8"
        },
        {
            "title": "020011110003-108-09-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=004&Type=8"
        },
        {
            "title": "020011110007-108-09-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=003&Type=8"
        },
        {
            "title": "020011110006-108-09-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=002&Type=8"
        },
        {
            "title": "020011110005-108-09-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001111&Seq=001&Type=8"
        }
    ]
}